Laverdia-CA1 is the first oral tablet FDA conditionally approved to treat lymphoma in dogs.
Features & Benefits
LAVERDIA-CA1 is a Selective Inhibitor of Nuclear Export (SINE) that binds to XP01, blocking the transport of tumor suppressor proteins, arresting the cell cycle to inhibit lymphoma cell growth and induce apoptosis